InDex Pharmaceuticals Holding AB Organisationsnummer: SE 559067-6820 Telefon: +46 (0)8 122 038 50 | Berzelius väg 13, 171 65 Solna, Sweden

InDex Pharmaceuticals Holding AB,559067-6820 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status

It can be a long snippet, a short snippet, whatever you prefer the size of card and description to be.This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. InDex Pharmaceuticals Holding AB (publ), org.nr 559067-6820, den koncern vari Bolaget är moderbolag eller ett dotterbolag i koncernen. Med ” Barclays ” avses Barclays Bank Ireland PLC, org.nr 396330 och med ” Carnegie ” avses Carnegie Invest- Index Pharmaceuticals, som utvecklar ett läkemedel mot tarmsjukdomen ulcerös kolit, gick i november ut med avsikten att ta in cirka 500 miljoner kronor genom en företrädesemission. Läs artikeln gratis genom att logga in eller skapa konto BioStock har analyserat läkemedelsutvecklingsbolaget InDex Pharmaceuticals Holding AB, som utvecklar nya behandlingsalternativ för immunologiska sjukdomar baserat på en bred portfölj av s.k. DIMS-substanser (DNA-baserade ImmunModulerande Sekvenser). Bolagets längst utvecklade läkemedelskandidat cobitolimod, som befinner sig i sen utvecklingsfas, har en ny typ av verkningsmekanism och ges InDex Pharmaceuticals Holding AB kallar till extra bolagsstämma 9 december 2020 – Aktieägarna i InDex Pharmaceuticals Holding AB, org. nr 559067-6820 (nedan news.cision.com Det verkar som det du letade efter inte kunde hittas.

Index pharmaceuticals holding

InDex Pharmaceuticals Holding AB (publ) kallar till. Det totala antalet aktier i bolaget ger utslag i Spotlights index. Indexet omfattar idéer: Index pharmaceuticals forum - InDex Pharmaceuticals — InDex Pharmaceuticals Holding AB (publ) är moderbolag i Koncernen 23 sep. 2019 — Index Pharmaceuticals Holding, listat på Nasdaq First North Growth Market, rådgavs av Setterwalls i samband med dess riktade nyemission av 17 apr. 2021 — Index pharma aktien: Index Pharma gör företrädesemission på cirka 533 - Finwire.

2021-03-29

The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation InDex Pharmaceuticals Holding visar ingen klar tre This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. It can be a long snippet, a short snippet, whatever you prefer the size of card and description to be.This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title.

INDEX PHARMA: SERVICEAVTAL MED PAREXEL FÖR FAS 3-STUDIE. STOCKHOLM (Nyhetsbyrån Direkt) Index Pharmaceuticals har ingått ett serviceavtal

Index Pharmaceuticals: Notice of Extraordinary General Meeting in InDex Pharmaceuticals Holding AB. December 9, 2020 - Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to an Extraordinary General Meeting on Tuesday 12 January, 2021 a InDex Pharmaceuticals Holding. 2 days ago 2 days ago Index Pharmaceuticals InDex Pharmaceuticals Holding AB offentliggör prospekt i samband med fullt garanterad företrädesemission (Cision) 2021-01-21 10:15 InDex Pharmaceuticals Holding AB operates as a pharmaceutical company.

2020-12-09 18:30. 9 december 2020 – Aktieägarna i InDex Pharmaceuticals Holding AB, org. nr 559067-6820 (nedan benämnt ”Bolaget”), kallas härmed till extra bolagsstämma tisdagen den 12 januari 2021 klockan 10.00 genom deltagande via förhandsröstning. Närvaro på stämman sker uteslutande genom poströstning. INDEX, InDex Pharmaceuticals Holding, (SE0008966295) Trading; Overview; Performance; Key Ratios; Financials; Fact Sheet ; Company Fact Sheet FAQ & Methodology 2021-01-21 Index Pharmaceuticals: The board of directors of InDex Pharmaceuticals Holding AB has resolved on a fully guaranteed rights issue of approximately MSEK 533. Publicerad: 2021-01-14 (Cision) Index Pharmaceuticals: Styrelsen för InDex Pharmaceuticals Holding AB har beslutat om en fullt garanterad företrädesemission om cirka 533 miljoner kronor 2 days ago Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) meddelar förändringar i valberedningens sammansättning inför årsstämman 2021: 15-03: Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting: 12-03 InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Barclays Global Healthcare Conference on Thursday March 11, 2021 and at … 2 days ago InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company’s lead drug candidate is Cobitolimod, which InDex Pharmaceuticals Holding är ett läkemedelsutvecklingsbolag med fokus på immunologiska sjukdomar.
Guido angeloni

2 days ago According to present data InDex Pharmaceuticals Holding AB (publ)'s INDEX shares and potentially its market environment have been in bearish cycle last 12 months (if exists). Currently there seems to be a trend where stocks in the Healthcare sector(s) are not very popular in this period. InDex Pharmaceuticals Holding AB (publ) year-end report 2020 Thu, Feb 25, 2021 08:00 CET. Financing secured for phase III development of cobitolimod “With the equity financing secured until the next pivotal read-out of clinical data, it feels very inspiring to now advance cobitolimod into phase III, which is the final stage of development before application for market approval,” says Peter InDex Pharmaceuticals Holding () Stock Market info Recommendations: Buy or sell InDex Pharmaceuticals Holding stock? Stockholm Stock Market & Finance report, prediction for the future: You'll find the InDex Pharmaceuticals Holding share forecasts, stock quote and buy / sell signals below.According to present data InDex Pharmaceuticals Holding's INDEX shares and potentially its … InDex Pharmaceuticals Holding AB Organisationsnummer: SE 559067-6820 Telefon: +46 (0)8 122 038 50 | Berzelius väg 13, 171 65 Solna, Sweden 2021-04-07. InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe.

Aktieportföljen · Aktiekurser · Aktieanalyser · ETF:er · Placeringsguidens 21 jan. 2021 — 21 januari, 2021 – Styrelsen i InDex Pharmaceuticals Holding AB (publ) (”InDex” eller “Bolaget”) har upprättat ett prospekt i samband med den Koncernöversikt. Telefonnummer.
Arriva 21 bus timetable shrewsbury

InDex Pharmaceuticals Holding AB (publ) today announced that the company has entered an agreement for services with global clinical research organization (CRO) Parexel Biotech for the phase III

En (1) teckningsrätt ger dig möjlighet att teckna, d v s köpa, en (1) ny aktie till kursen 1,20 SEK per aktie av serie B. Teckningsrätterna kommer att bokas in på din depå 2021-01-25. Om du vill vara med i emissionen så måste du göra följande: InDex Pharmaceuticals Holding är ett läkemedelsutvecklingsbolag med fokus på immunologiska sjukdomar. Bolagets främsta tillgång är läkemedelskandidaten cobitolimod som är i sen klinisk utvecklingsfas för behandling av måttlig till svår aktiv ulcerös kolit. 2 dagar sedan · STOCKHOLM, April 23, 2021 /PRNewswire/ — InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2020.

InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the

InDex Pharmaceuticals Holding AB (publ) today announced that the company has entered an agreement for services with global clinical research organization (CRO) Parexel Biotech for the phase III InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis 30 March 2021 - Other press release. InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting 15 March 2021 - Other press release. April 23, 2021 - InDex Pharmaceuticals Holding AB today publishes the Annual Report for 2020. The Annual Report is attached as a PDF and is available on the company's website, | April 23, 2021 InDex Pharmaceuticals Holding AB (publ) is the parent company of the Group, which also includes InDex Pharmaceuticals AB and InDex Pharmaceuticals AB’s wholly owned subsidiary InDex Diagnostics AB. InDex Pharmaceuticals Holding AB operates as a pharmaceutical company. The Company develops, produces, and sells medicines for the treatment of ulcerative colitis and immunological diseases. Mailing address InDex Pharmaceuticals Holding AB (publ) Berzelius väg 13 171 65 Solna, Sweden Phone: +46 (0)8 122 038 50 E-mail: info@indexpharma.com Registration number: SE 559067-6820 Visiting add 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic.

InDex Pharmaceuticals — Få detaljerad information om InDex Pharmaceuticals Holding AB (INDEX) Nyckeltalshistorik för InDex Pharmaceuticals. 10 års historiska nyckeltal och branschjämförelse. Aktiekurs till Excel. Översikt Värdering Utdelning & FCF för 4 dagar sedan — Aktieanalys InDex Pharmaceuticals Holding som tillhör Hälsovård sektorn är en Medium risk aktie. InDex Pharmaceuticals Holding aktien InDex Pharmaceuticals Holding AB. 5590676820. Beställ rapport med detaljerad information om ägarandelar och rösträtter i aktiebolaget (se exempelrapport). ANNONS STÄNG.